不同序贯的C225与化疗药物对人胃腺癌细胞株SGC-7901的抗瘤作用影响

摘要

Objective To evaluate inhibition effecton proliferation of SCG - 7901 cell in different sequences combination of Cetuximab with either oxaliplatin, funaioniding or Capecitabine. To explore the optimal treatment schedule of combination of Cetuximab and cytotoxic drugs. Methods Increasing concentration of Cetuximab( 5 ~ 500 mg/L ) combined with increasing concentration cytotoxic drugs was administrated to human gastric cancer cell lines SCG - 7901 with different sequences. The proliferation inhibition effect on SCG - 7901 cell was detected with CCK - 8 assay. The IC50 and CI of Cetuximab and either cytotoxic drugs were calculated. Results The combination of a cytotoxic drug with Cetuximab caused different antiproliferative effecs on SCG -7901 cells depending on different treatment sequences. The respective IC50 of Cetuximab and cytotoxic drugs decreased when Cetuximab followed by chemotherapy, while the CI values were all >1 , which indicated an antagonistic interaction. "In contrast, when chemotherapy was followed by Cetuximab, the respective IC50 of drugs decreased more remarkably and the CI values were all < 1, which indicated a significant synergistic antiproliferative activity. Conclusion Monoclonal antibody and cytotoxic drugs to SGC -7901 cell lines is antiproliferative activity. The optimal treatment sequence is chemotherapy followed by Cetuximab. It can obtain obviously synergistic activity and conduce to less doses and milder side effects in clinical application.%目的 探讨不同序贯的西妥昔单抗(Cetuximab,C225)与化疗药物联合对人胃腺癌细胞株SGC-7901的增殖抑制作用,寻找治疗胃癌的新方法、新配方.方法 选用浓度递增的Cetuximab和化疗药物奥沙利铂、氟尿嘧啶、卡培他滨,分别按照不同给药方式单药、序贯作用于SGC-7901细胞,采用细胞计数试剂盒检测不同给药方式对SGC-7901细胞的增殖抑制作用,计算不同序贯给药时Cetuximab和化疗药物的半数抑制浓度(IC50)的变化,及其相互作用的协同系数(CI).结果 Cetuximab和化疗药物联用对SGC-7901细胞的增殖抑制作用受给药序贯影响:Cetuximab先于化疗药物给药,两者的IC50较单用时降低,但CI值均大于1,两者之间为拮抗效应;Cetuximab后于化疗药物给药,两者的IC50较单用时降低更为明显,且CI值均小于1,两者之间具有较明显的协同效应.结论 Cetuximab联合化疗药物对胃癌细胞SGC-7901的增殖具有协同抑制作用,化疗药物先于Cetuximab的序贯给药方式能获得明显的协同效应.